Non-Small Cell Adenocarcinoma

histology

Identifier: CI-CAN-00003439
Entity page: /cancer/non-small-cell-adenocarcinoma ↗
Edges: 785

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Non-Small Cell Adenocarcinoma altered in cohorts of …ALTERED_INderived15 of 492show all (up to 200)
← altered in cohorts of	RYR2 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 11 cohorts	—	—	Lung Adenocarcinoma	11	Observed	gdc	graph →
← altered in cohorts of	FLG 406 / 573 cases (71 %) · ssm · TCGA-LUAD · largest of 9 cohorts

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

EGFR G719A Afatinib0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L861Q Afatinib0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR S768I Afatinib0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR Exon 19 Deletion Afatinib0 active / 1 trials
Curatedlevel Bsensitivity· support 4civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L858R Afatinib0 active / 1 trials
Curatedlevel Bsensitivity· support 3civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L858R Erlotinib0 active / 5 trials
Curatedlevel Bsensitivity· support 3civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR L858R Gefitinib0 active / 7 trials
Curatedlevel Bsensitivity· support 3civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma
EGFR Exon 19 Deletion Erlotinib0 active / 5 trials
Curatedlevel Bsensitivity· support 2civicObservedEGFR altered in 33% (866 / 2,653 cases, largest of 16 cohorts)no approval record in this cancercontext: Lung Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Non-Small Cell Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 57show all (up to 200)
→ investigated in trials for	Carboplatinsmall molecule 20 trials (7 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 18 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 15 trials (4 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 15 trials (4 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 13 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 9 trials (5 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 8 trials (5 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinib Hydrochloridesmall molecule 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Gefitinibsmall molecule 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall molecule 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Small Cell Adenocarcinoma	3	Observed	clinicaltrials	graph →

Non-Small Cell Adenocarcinoma studied in …STUDIED_INderived10 of 236show all (up to 200)
→ studied in	NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04105270Phase 2 · recruiting RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial · condition mapped ALIAS · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07341737Phase 1/Phase 2 · recruiting SL-28 for Advanced Solid Tumours · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05198830Phase 2 · active not recruiting Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00334815Phase 2 · active not recruiting Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05517811recruiting Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05797168Phase 1/Phase 2 · recruiting Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04557449Phase 2 · active not recruiting Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors · condition mapped ALIAS · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04929041Phase 2/Phase 3 · active not recruiting Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative · condition mapped ONTOLOGY_EXACT · 236 trials mapped (76 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →